Victory Capital Management
ONCT

Victory Capital Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Victory Capital Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-205
Closed -$12K – 3444
2020
Q1 		$12K Buy
+205
New +$15.3K ﹤0.01% 3266
2019
Q4 		– Sell
-23
Closed -$2K – 3432
2019
Q3 		$2K Buy
+23
New +$2.35K ﹤0.01% 3665

Other funds holding ONCT

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DY
Dowling & Yahnke San Diego, California $2.15B AUM 10.82% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
AAM
Aureus Asset Management Boston, Massachusetts $1.5B AUM 20.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Victory Capital Management's ONCT Position: Q2 2020 in Review

Victory Capital Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q2 2020, closing a stake of 205 shares — an estimated $12K sold.

Victory Capital Management first reported a position in ONCT in Q3 2019 and held it in 2 quarters. The position peaked at $12K in Q1 2020. 20 funds tracked by Wall St. Rank hold ONCT as of Q2 2020.

  • Victory Capital Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 205 Oncternal Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $12K.
  • Victory Capital Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $12K in Q1 2020.
  • 20 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.